Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 7/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927743 | 0.87 | PPARA (0.39) | PPARACYP4F2CYP4A11DHODHMCL1 | |
| SCHEMBL6488936 | 0.81 | PPARA (0.46) | PPARAFBP1 | |
| SCHEMBL6502479 | 0.80 | PDE3B (0.50) | PDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6923484 | 0.76 | MCL1 (0.47) | PPARADHODHPDE3BPDE3AP2RY12 | |
| SCHEMBL6499830 | 0.72 | PDE3B (0.49) | PDE3BPDE3AP2RY12MCL1 | |
| SCHEMBL6502505 | 0.71 | AR (0.43) | DHODHACACBMME | |
| SCHEMBL6924904 | 0.70 | DHODH (0.39) | PPARADHODHACACBMME | |
| SCHEMBL6487097 | 0.70 | CA12 (0.46) | ACACBMME | |
| SCHEMBL6466693 | 0.69 | CYP4F2 (0.50) | PPARACYP4F2CYP4A11MCL1 | |
| SCHEMBL3962137 | 0.69 | DHODH (0.43) | DHODHMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARA 665/4885CYP4F2 279/4885CYP4A11 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.